The implications of P-glycoprotein in HIV: friend or foe?
P-glycoprotein (P-gp), coded by the ABCB1 gene, has a wide tissue distribution. The drug transporter is known to limit the bioavailability of a plethora of drugs and xenobiotics including the human immunodeficiency virus (HIV) protease inhibitors. There remains a considerable degree of debate in the literature with respect to the role of ABCB1 polymorphisms in HIV-treatment outcome and some studies have also implicated antiretroviral drugs as inducers of P-gp. Recent evidence indicates a role for P-gp in the inhibition of viral infectivity and/or release and cellular relationships with other infection-related proteins (and cholesterol). It is becoming increasingly clear that future studies on P-gp in HIV should consider both pharmacological and virological issues.
Owen
Andrew
A
Department of Pharmacology and Therapeutics, The University of Liverpool, 70 Pembroke Place, Liverpool, L69 3GF, UK. aowen@liv.ac.uk
Chandler
Becky
B
Back
David J
DJ
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000502:physiology*; D000818:Animals; D019380:Anti-HIV Agents / Q000378:metabolism / Q000494:pharmacology*; D023241:Antiretroviral Therapy, Highly Active; D002352:Carrier Proteins / Q000378:metabolism; D006678:HIV / Q000187:drug effects; D015658:HIV Infections / Q000188:drug therapy / Q000378:metabolism*; D006801:Humans
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D019380:Anti-HIV Agents; D002352:Carrier Proteins